SRI researchers have developed non-natural peptide-like polymers, called Techneins, that have the potential to be used as therapeutics and diagnostic tools. Next week, Christopher Apostol will be at the University of Arizona discussing applications of Techneins as high affinity binders of SARS-CoV2 and as potential medical countermeasures to combat the opioid crisis. Interested in learning about Techneins? Visit: https://lnkd.in/er46ji7s #precisionmedicine #drugdevelopment #covid
SRI Biosciences
生物技术研究
Menlo Park，California 1,080 位关注者
Developing next-gen drugs, diagnostics, and technologies to solve unmet medical needs and propel innovation to market.
关于我们
SRI Biosciences—a division of SRI—conducts cutting-edge research, invents new platform technologies to advance biomedical discovery, and delivers next-generation drugs, diagnostics, and devices to solve unmet medical needs. We work with commercial, government, and academic clients and partners to develop transformative approaches and platforms for the toughest therapeutic challenges. Our pioneering research in human sleep, immuno-oncology, drug delivery, point-of-care diagnostics, therapeutic discovery, and more aims to help save and improve lives worldwide.
- 网站
-
https://www.sri.com/biomedical-sciences/
SRI Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Menlo Park，California
- 领域
- drug discovery、drug development、formulation development、pharmacology/toxicology、medicinal chemistry、automated chemical synthesis、neuroscience、human sleep research、proteomics、diagnostics、immuno-oncology、targeted drug delivery、intracellular drug delivery、nucleic acid delivery、biological assay development、high-throughput screening、CRISPR、medical imaging、virology和nonclinical development
动态
-
SRI researchers are developing an affordable, shelf-stable anti-malarial drug formulation that could provide months of protection with just a single injection. Learn more about the research by Gita Shankar and team: https://lnkd.in/eu4hv9fR #drugdevelopment #malaria #vaccine
-
-
SRI has been a leader for decades in the development of tools, technologies, and therapeutics that have saved and improved countless lives around the world. Our Biosciences division works with government and commercial clients to integrate basic and translational research, drug discovery, and nonclinical and clinical development. Learn about how we’re innovating in health and connect with us: https://lnkd.in/eegk_faF #precisionmedicine #biomedical #drugdiscovery
-
-
SRI Biosciences is at EBD Group #BioEurope Conference this week! We’re actively seeking commercial partners and look forward to discussing our proprietary FOX Three Molecular Guidance System? (MGS) that enables intracellular delivery of a variety of biotherapeutic cargos to targets that have previously been unreachable. Attending #BioEurope and interested in learning more about FOX Three? Connect with us in the partnering portal: https://lnkd.in/dCbGGu3z More on FOX Three MGS: https://lnkd.in/g65HJvt4 #precisionmedicine #drugdelivery Melissa M. Wagner Kathlynn Brown
-
-
On Sunday, we “fall back” one hour as we reach the end of Daylight Saving Time. While setting the clocks back allows us an extra hour of sleep, the change does impact the body’s circadian rhythm. SRI’s Human Sleep Lab conducts sleep research focusing on circadian rhythm, menopause, wearable technology, insomnia and beyond. Learn more here: https://lnkd.in/gjwP2rQP Fiona Baker #daylightsaving #sleepresearch
-
-
“SRI’s commercial solutions are tailored to meet the specific needs of its clients, and the institute has a proven track record of delivering value and driving innovation,” Peter Marcotullio, Senior Vice President of Commercialization. Congratulations on your new role, Peter Marcotullio!
We're thrilled to announce that Peter Marcotullio has been named SRI’s new Senior Vice President of Commercialization. Peter brings over 25 years of experience at SRI in our commercialization, licensing, and patent development areas. Join us in congratulating Peter as he continues leading SRI’s efforts to deliver innovative solutions that address critical global challenges through various commercial pathways. Read more: https://bit.ly/3YC852z
-
-
SRI has developed a platform, called DiaCyt, that has identified peptides that mediate drug delivery across the blood-brain barrier — enabling effective delivery of therapeutics to previously unreachable targets. Learn more about DiaCyt: https://lnkd.in/eSct4AYx Attending EBD Group #BioEurope conference in November and want to connect on DiaCyt? Contact us in the partnering portal: https://lnkd.in/dCbGGu3z #precisionmedicine #drugdelivery
-
-
SRI Biosciences will be at #BioEurope in Stockholm, Sweden in 3 weeks! Our focus is on drug development and drug delivery platforms with applications in a variety of therapeutic areas such as cardiovascular, metabolic, lung and kidney disease, immuno-oncology, solid tumor targeting, and more. We’re seeking commercial partners for our novel precision medicine platform — Targeted Antigen Loaded Liposomes (TALL) — a solution that aims to enhance and advance immunotherapy by enabling a cold tumor to turn to hot. Learn about TALL: https://lnkd.in/gwzE-TK4 Connect with us in the EBD Group partnering portal: https://lnkd.in/dCbGGu3z #immunotherapy #precisionmedicine
-
-
Attending the 2024 AAPS conference? Join SRI’s nagireddy dumpa as he shares a case study on formulation development and manufacturing of a drug product using spray drying for enhanced solubility and bioavailability. Not attending the conference? Learn more about our drug development services here: https://lnkd.in/e-Mq3JBX American Association of Pharmaceutical Scientists (AAPS) | @aapscomms #PharmSci360 #drugdevelopment #clinicalmanufacturing
-
-
SRI researchers are studying how menopause can affect sleep and women’s physical and mental health. In a recent Q&A, Fiona Baker discusses the mechanisms behind menopausal insomnia, its prevalence, and effective management strategies. Read the Q&A: https://lnkd.in/etFp2eFU #womenshealth #menopause #mentalhealth
-